Exforge and Bydureon drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Exforge (amlodipine besylate; valsartan) and Bydureon (exenatide synthetic). Common drug interactions include injection site haemorrhage among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Exforge and Bydureon. It is created by eHealthMe based on reports of 26 people who take the same drugs from the FDA, and is updated regularly.

What is Exforge?

Exforge has active ingredients of amlodipine besylate; valsartan. It is often used in high blood pressure. eHealthMe is studying from 13,350 Exforge users. Check the latest studies of Exforge.

What is Bydureon?

Bydureon has active ingredients of exenatide synthetic. It is often used in type 2 diabetes. eHealthMe is studying from 24,309 Bydureon users. Check the latest studies of Bydureon.

On Aug, 01, 2026

26 people who take Exforge and Bydureon together, and have interactions are studied.

What are the common drug interactions of Exforge and Bydureon, by gender? *:

female:

Injection site haemorrhage (bleeding from injection site)
Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
Glycosylated haemoglobin increased
Nausea (feeling of having an urge to vomit)
Weight decreased
Alopecia (absence of hair from areas of the body)
Blood cholesterol increased
Blood glucose decreased
Blood insulin decreased
Chronic kidney disease

male:

Diarrhoea
Myalgia (muscle pain)
Hypoglycaemia (deficiency of glucose in the bloodstream)
Hypotension (abnormally low blood pressure)
Injection site induration
Injection site nodule (small swelling or aggregation of cells in the body, esp. an abnormal one at injection site)
Nocturia (the need to get up in the night to urinate)
Pain in extremity
Arthralgia (joint pain)
Injection site extravasation (flow of (blood or lymph) from injection site)

What are the common drug interactions of Exforge and Bydureon, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Blood cholesterol increased
Injection site injury
Injection site mass
Injection site pain
Malaise (a feeling of general discomfort or uneasiness)
Vision blurred

50-59:

Myalgia (muscle pain)
Diarrhoea
Drug ineffective
Fatigue (feeling of tiredness)
Gait disturbance
Injection site pain
Injection site pruritus (severe itching at injection site)
Nodule (a growth of abnormal tissue)
Arthralgia (joint pain)
Injection site extravasation (flow of (blood or lymph) from injection site)

60+:

Decreased appetite
Constipation
Glycosylated haemoglobin increased
Injection site nodule (small swelling or aggregation of cells in the body, esp. an abnormal one at injection site)
Adverse event
Alopecia (absence of hair from areas of the body)
Amylase increased
Blood glucose decreased
Blood insulin decreased
Confusional state

What are the existing conditions these people have? *

Diabetes: 8 people, 30.77%
High Blood Pressure: 7 people, 26.92%
High Blood Cholesterol: 6 people, 23.08%
Blood Pressure Abnormal: 3 people, 11.54%
Pain: 2 people, 7.69%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 7.69%
Dyslipidaemia (abnormal amount of lipids): 2 people, 7.69%
Depression: 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Exforge and Bydureon?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously